SIGA Technologies is a commercial-stage pharmaceutical company specializing in health security and infectious disease countermeasures, primarily centered around its antiviral drug TPOXX (tecovirimat). The company maintains a robust balance sheet with approximately $145.6 million in cash and zero debt, allowing it to return capital to shareholders via special dividends (such as the $0.60 per share dividend paid in April 2026). However, SIGA's financial performance is highly variable and dependent on the timing of government procurement orders. While Q1 2026 saw minimal product deliveries resulting in a net loss of $3.5 million, management has clear near-term revenue visibility with $39 million in planned deliveries across Q2 and Q3 2026. A 'Hold' recommendation is appropriate as the company navigates lumpy procurement cycles and regulatory headwinds, such as the European CHMP's recommendation to withdraw the mpox indication for TPOXX, while continuing to leverage its strong U.S. government partnership.